Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Reports | Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market

Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market

After 3 years of steady growth, the value of the insomnia market across the seven major markets (7MM) slumped by 12% to $4.1 billion in 2007 due to rapid generic erosion of Sanofi-Aventis's market leader Ambien (zolpidem) in the US. However, this downturn will be short-lived and the market will regain growth from 2009 to $6.9 billion in 2017 driven by the launch of new treatments across the 7MM.

This report gives a strategic analysis of the likely impact that recent events will have on the future insomnia market

Includes insomnia-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017

This report provides a global market snapshot by including insomnia-specific sales analysis for leading brands outside the seven major markets

Key conclusions are supported by key opinion leader comment

During 2007, US sales of Ambien CR overtook sales of Lunesta indicating that Sanofi-Aventis' attempt to switch patients from Ambien to Ambien CR has been successful. Ambien CR is forecast to become the market leader in 2017, achieving sales of over $1.5 billion.

Actelion's orexin receptor antagonistalmorexantis forecast to be the main driver of pipeline sales products, contributing blockbuster revenues by 2017. This is higher than previous forecasts due to Actelion's recent commercialization deal with GlaxoSmithKline, which will enable the realization of almorexant's full commercial potential

Neurim and Lundbeck's Circadin (controlled release melatonin) is the most recent entry to the insomnia market in Germany and it is expected that the drug will be rolled out in remaining EU countries later in 2008. Due to an uncompetitive clinical profile Datamonitor forecasts sales of Circadin to be small compared to other leading brands

Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2007 to 2017

Quantify the current size of the seven major markets and the trends in the rest of the world

Assess the impact of events, such as patent expiries and new product launches, on the insomnia-specific sales of key brand name products

Publication: 39661
Library Code: DMHC2438
Type: Report
Format: PDF & DataPack
Pages: 148

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions